Quantcast

Latest Antithrombin Stories

2010-10-19 16:17:26

Finding may lead to better understanding and earlier detection of breast cancer A new technique that searches blood for the tiniest remnants of broken down proteins has revealed new information about how cells crank up cancer activators called proteases. The results improve researchers' understanding of the mechanics of breast cancer and point to where to look for possible indicators of early disease. Appearing this week in PLoS ONE, the research shows previously unknown contributing factors...

2009-08-26 08:47:25

It is known that I/R induces an inflammatory response deleterious to the organ involved but also to the system as a whole. Mesenteric ischemia occurs when the veins or arteries that supply blood to the intestine are obstructed. In transplants, the organ undergoes total (arterial and venous) I/R. Few available treatments exist. Greater knowledge of these conditions would aid in the search for new therapies. However, the precise nature of the response arises after venous, arterial or total...

2009-07-16 14:04:46

Dosing algorithms allow for normalization of antithrombin levels during specific high-risk situations for patients with hereditary anithrombin deficiency Data presented at the annual meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Boston show that ATryn® (Antithrombin [Recombinant]) safely prevents peri-operative and peri-partum acute deep vein thrombosis (DVT) or other venous thromboembolic events in patients with hereditary antithrombin...

0268fcfcd0b40d3acd761bc24cda9a891
2009-01-08 06:50:00

Does your family have a history of blood clots? If you do, the good news is that the newest anti-clotting medication is moving closer to distribution in the US. The interesting and unusual thing about the drug is that that is made from"¦. goat's milk.The scientific first, the drug, prepared from the milk of genetically engineered goats received approval from the experts at the Food and Drug Administration. The FDA has announced that the medication is effective and safe.Named ATryn, the...

2008-10-06 09:00:57

The US Food and Drug Administration, or FDA, has accepted for review GTC Biotherapeutics, Inc.'s ("GTC", Nasdaq: GTCB) Biologics License Application, or BLA, for ATryn(R). FDA's Blood Products Advisory Committee intends to review the BLA for ATryn(R) during a meeting that is being planned for January 2009. Based on the achievement of these milestones, GTC has received $2 million in additional milestone payments from OVATION Pharmaceuticals, Inc. As previously announced, ATryn(R) has been...

2008-09-21 03:00:12

By Gosk-Bierska, I Wysokinski, W; Karnicki, K; Adamiec, R Aim. Thrombus formation plays a critical role in pathogenesis of cardiovascular complications in atherosclerotic peripheral arterial occlusive disease (PAOD). Tissue factor (TF) initiates the clotting cascade and is considered an important regulator of hemostasis and thrombosis. TF activity is regulated by TF pathway inhibitor (TFPI). The aim of our study was to evaluate plasma levels of the TF, TFPI and their relation to coagulation...

2008-09-05 09:00:37

GTC Biotherapeutics, a developer of recombinant blood proteins, has announced that the FDA has assigned priority review to the company's biologic license application for ATryn. Priority review is granted to applications for products that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease. Under priority review, the FDA's target date for action on the biologic license...

2008-08-14 09:01:15

GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced the closing of its previously announced collaboration agreement with OVATION Pharmaceuticals, Inc. ("OVATION") to develop and market ATryn(R) in the United States. ATryn(R) is GTC's recombinant form of human antithrombin, a plasma protein with anticoagulant and anti-inflammatory properties. The agreement includes $257 million in potential payments to GTC for meeting clinical, regulatory, and sales milestones, including a $3 million...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.